Skip to main content
SpringerLink
Log in

Screening of Prostate Cancer

  • Living reference work entry
  • First Online:
Urologic Oncology

  • 278 Accesses

Abstract

In this chapter we aim to give insight in the burden of prostate cancer and the effects of early detection and treatments using ample available data from cancer registries and (randomized) clinical trials. Prostate cancer is the leading cancer type in men, and it occurs mainly at age 60–80 remaining asymptomatic during lifetime in many cases. The impact of a disease determines the need and extent of screening. Large-scale population-based prostate cancer screening trials mainly aimed to demonstrate a reduction in disease-specific mortality. After two decades it became clear that disease-specific mortality could be reduced, but at considerable harms including over diagnosis and related overtreatment. Interpretation of trial data is however hampered by, e.g., prostate-specific antigen (PSA) contamination of the control group and the continuous development of new diagnostic tools and treatment options. Nowadays, prostate cancer morbidity and quality of life are at least equally important as survival. Diagnostic strategies in prostate cancer screening protocols are now directed at trying to detect higher-risk prostate cancers in a really early phase and trying to avoid detection of low-volume, low-grade cancers. The ideal test does not (yet) exist meaning that clinically insignificant tumors will still be diagnosed and significant tumors can be missed. Until more advanced markers and diagnostic tools, less invasive treatments, and better active surveillance strategies combined into an individually tailored algorithm demonstrate a substantially better cost-effective impact, the decision whether or not to screen remains a shared decision between men and their physicians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abdollah F, Sun M, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, Tian Z, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, Briganti A. Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. Eur Urol. 2012;62(1):42–52.

    Article  PubMed  Google Scholar 

  • Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, Hawkes D, Barratt DC, Emberton M. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol. 2011;186(2):458–64.

    Article  PubMed  Google Scholar 

  • Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, P. s. group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.

    Article  PubMed  Google Scholar 

  • Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, Team PP. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Arsov C, Becker N, Hadaschik BA, Hohenfellner M, Herkommer K, Gschwend JE, Imkamp F, Kuczyk MA, Antoch G, Kristiansen G, Siener R, Semjonow A, Hamdy FC, Lilja H, Vickers AJ, Schroder FH, Albers P. Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial. Eur Urol. 2013;64(6):873–5.

    Article  PubMed  Google Scholar 

  • Bertsimas D, Silberholz J, Trikalinos T. Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening. Health Care Manag Sci. 2016.

    Google Scholar 

  • Bjorklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O. Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study. BJU Int. 2016;118(2):302–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Black W, Ling A. Is earlier diagnosis really better? The misleading effects of lead time and length biases. AJR Am J Roentgenol. 1990;155(3):625–30.

    Article  CAS  PubMed  Google Scholar 

  • Boehm K, Larcher A, Beyer B, Tian Z, Tilki D, Steuber T, Karakiewicz PI, Heinzer H, Graefen M, Budaus L. Identifying the most informative prediction tool for cancer-specific mortality after radical prostatectomy: comparative analysis of three commonly used preoperative prediction models. Eur Urol. 2016;69(6):1038–43.

    Article  PubMed  Google Scholar 

  • Bokhorst LP, Kranse R, Venderbos LD, Salman JW, van Leenders GJ, Schroder FH, Bangma CH, Roobol MJ, E. R. S. Group. Differences in treatment and outcome after treatment with curative intent in the screening and control arms of the ERSPC rotterdam. Eur Urol. 2015;68(2):179–82.

    Article  PubMed  Google Scholar 

  • Carlsson SV, Roobol MJ. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. Curr Opin Urol. 2017;27:198–204.

    Article  PubMed  Google Scholar 

  • Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Paez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: a microsimulation screening analysis. Cancer. 2016;122(21):3386–93.

    Article  PubMed  PubMed Central  Google Scholar 

  • Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267(16):2215–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Center MSKC. https://www.mskcc.org/nomograms/prostate. From https://www.mskcc.org/nomograms/prostate. 2017. Accessed 11 Feb 2017.

  • Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330(4):242–8.

    Article  CAS  PubMed  Google Scholar 

  • Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194(6):1537–47.

    Article  PubMed  Google Scholar 

  • Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.

    Article  PubMed  Google Scholar 

  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  • De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, E.-W. Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol. 2014;15(1):23–34.

    Article  PubMed  Google Scholar 

  • Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  • Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK, Wilson TG, Zattoni F, Montorsi F. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012a;62(3):418–30.

    Article  PubMed  Google Scholar 

  • Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A, Menon M, Montorsi F, Patel VR, Stolzenburg JU, Van der Poel H, Wilson TG, Zattoni F, Mottrie A. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012b;62(3):405–17.

    Article  PubMed  Google Scholar 

  • Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017;14(1):26–37.

    Article  CAS  PubMed  Google Scholar 

  • Force, U. S. P. S. T. Screening for prostate cancer: recommendation and rationale. Ann Intern Med. 2002;137(11):915–6.

    Article  Google Scholar 

  • Force, U. S. P. S. T. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185–91.

    Article  Google Scholar 

  • Gaudreau PO, Stagg J, Soulieres D, Saad F. The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements. Biomark Cancer. 2016;8(Suppl 2):15–33.

    PubMed  PubMed Central  Google Scholar 

  • Gondos A, Krilaviciute A, Smailyte G, Ulys A, Brenner H. Cancer surveillance using registry data: results and recommendations for the Lithuanian national prostate cancer early detection programme. Eur J Cancer. 2015;51(12):1630–7.

    Article  PubMed  Google Scholar 

  • Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16(16):1667–76.

    Article  PubMed  Google Scholar 

  • Guessous I, Cullati S, Fedewa SA, Burton-Jeangros C, Courvoisier DS, Manor O, Bouchardy C. Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities. Prev Med. 2016;82:83–91.

    Article  PubMed  Google Scholar 

  • Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis. 2017;20(1):12–9.

    Article  CAS  PubMed  Google Scholar 

  • Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60–7.

    Article  CAS  PubMed  Google Scholar 

  • Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet. 1989;1(8642):799–803.

    Article  CAS  PubMed  Google Scholar 

  • Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML. Patients’ perceptions of the side-effects of prostate cancer treatment – a qualitative interview study. Soc Sci Med. 2006;63(4):911–9.

    Article  PubMed  Google Scholar 

  • Korfage IJ, de Koning HJ, Essink-Bot ML. Response shift due to diagnosis and primary treatment of localized prostate cancer: a then-test and a vignette study. Qual Life Res. 2007;16(10):1627–34.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kweldam CF, Kummerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, Roobol MJ, van Leenders GJ. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol. 2016;29(6):630–6.

    Article  PubMed  Google Scholar 

  • Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer. 2010;46(17):3095–101.

    Article  CAS  PubMed  Google Scholar 

  • Loeb S, Lilja H, Vickers A. Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol. 2016;26(5):459–65.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL. Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer. Eur Urol. 2015;68(5):805–11.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mohler JM. NCCN guidelines, prostate cancer version 1. 2017.

    Google Scholar 

  • Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.

    Article  PubMed  Google Scholar 

  • Murray NP, Reyes E, Orellana N, Fuentealba C, Jacob O. Head to head comparison of the chun nomogram, percentage free PSA and primary circulating prostate cells to predict the presence of prostate cancer at repeat biopsy. Asian Pac J Cancer Prev. 2016;17(6):2941–6.

    PubMed  Google Scholar 

  • Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, Henderson D, Casamassima F, Orecchia R, Surgo A, Brown L, Tree A, Miralbell R, De Meerleer G. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12.

    Article  PubMed  Google Scholar 

  • Popiolek M, Rider JR, Andren O, Andersson SO, Holmberg L, Adami HO, Johansson JE. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013;63(3):428–35.

    Article  PubMed  Google Scholar 

  • Porres D, Pfister D, Heidenreich A. Minimally invasive treatment for localized prostate cancer. Minerva Urol Nefrol. 2012;64(4):245–53.

    CAS  PubMed  Google Scholar 

  • Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J Urol. 2016;196(6):1613–8.

    Article  PubMed  Google Scholar 

  • Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A and ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.

    Google Scholar 

  • Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly. Cancer. 2012;118(12):3062–70.

    Article  PubMed  Google Scholar 

  • Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO trial. N Engl J Med. 2016a;374(18):1795–6.

    Article  PubMed  Google Scholar 

  • Shoag JE, Mittal S, Hu JC, et al. More on reevaluating PSA testing rates in the PLCO trial. N Engl J Med. 2016b;375(15):1500–1.

    Article  PubMed  Google Scholar 

  • Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009;27(21):3459–64.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tabuchi T, Nakayama T, Fukushima W, Matsunaga I, Ohfuji S, Kondo K, Kawano E, Fukuhara H, Ito Y, Oshima A. Determinants of participation in prostate cancer screening: a simple analytical framework to account for healthy-user bias. Cancer Sci. 2015;106(1):108–14.

    Article  CAS  PubMed  Google Scholar 

  • Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13(4):205–15.

    Article  PubMed  PubMed Central  Google Scholar 

  • van den Bos W, Muller BG, Ehdaie B, Scardino P, de la Rosette JJ. What is still needed to make focal therapy an accepted segment of standard therapy? Curr Opin Urol. 2014;24(3):247–55.

    Article  PubMed  Google Scholar 

  • Venderbos LD. Long-term follow-up after active surveillance or curative treatment: quality of life outcomes of men with low-risk prostate cancer. Qual Life Res. 2017;26(6):1635–45.

    Article  PubMed  PubMed Central  Google Scholar 

  • Venderbos LD, van den Bergh RC, Roobol MJ, Schroder FH, Essink-Bot ML, Bangma CH, Steyerberg EW, Korfage IJ. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psycho-Oncology. 2015;24(3):348–54.

    Article  PubMed  Google Scholar 

  • Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, Van den Bergh R, Van Poppel H, Valdagni R, Bellardita L. Setting an agenda for assessment of health-related quality of life among men with prostate cancer on active surveillance: a consensus paper from a European School of Oncology Task Force. Eur Urol. 2017;71(2):274–80.

    Article  PubMed  Google Scholar 

  • Weber MF, Cunich M, Smith DP, Salkeld G, Sitas F, O'Connell D. Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study. BMC Public Health. 2013;13:429.

    Article  PubMed  PubMed Central  Google Scholar 

  • Whiting PF, Moore TH, Jameson CM, Davies P, Rowlands MA, Burke M, Beynon R, Savovic J, Donovan JL. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016;118(2):193–204.

    Article  PubMed  Google Scholar 

  • Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schroder FH, van der Kwast TH. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol. 2011;185(1):121–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands

    Martijn B. Busstra & Monique J. Roobol

Authors
  1. Martijn B. Busstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monique J. Roobol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martijn B. Busstra .

Editor information

Editors and Affiliations

  1. Dept. of Urology & Urologic Oncology, Hannover Medical School, Hannover, Germany

    Axel S. Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Martini-Klinik am UKE GmbH, Martinistr. 52, D22047, Hamburg, Germany

    Thomas Steuber

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Busstra, M.B., Roobol, M.J. (2017). Screening of Prostate Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_67-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_67-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation